The impacts of BCOR or BCORL1 mutations have previously been described in 28 of the 377 de novo AML cases (7%) [24], and were independent unfavorable prognostic factors in both OS (p = 0.004) and RFS (p = 0.046). This evidence concerns the gene BCOR and acute myeloid leukemia.